Intent to Sole Source - Biolegend Oliogos
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute of Health, Clinical Center (NIH-CC), under the Department of Health and Human Services, has issued a Special Notice indicating its intent to award a sole-source contract to Biolegend for Custom Oligios. This acquisition is for the PACT team at CCE to conduct single cell copy number analysis for CAR-T cell products. This is not a request for proposal.
Scope of Work
The requirement is for Custom Oligios to be used by the PACT team at CCE. These Oligios are essential for performing single cell copy number analysis with a Tapestri instrument, specifically for CAR-T cell products. This analysis supports clinical Quality Control (QC) assays.
Contract & Timeline
- Type: Notice of Intent to Sole Source (Special Notice)
- Intended Contractor: Biolegend
- Justification: 41 U.S.C. 253(c)(1) as implemented by FAR 6.302-1 (only one responsible source).
- Product/Service Code: 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits And Sets)
- Place of Performance: Bethesda, MD
- Published: April 29, 2026
- Capability Statement Due: May 8, 2026, by 12:00 PM Eastern Standard Time
Response Information
Responsible sources who believe they can provide the required Custom Oligios may submit a capability statement. These statements must be sent via email to valerie.gregorio@nih.gov. The subject line of the email must reference NOI-OLAO-CC-26-004813. All responses received by the closing date will be considered, but a determination not to compete this requirement remains solely at the Government's discretion.